Jakarta, 29 September 2023
Domestic vaccine independence is one of the government's efforts in health transformation, especially in the third pillar. Among others, by establishing cross-sector coordination for research networks, technology transfer and global cooperation for innovation.
As an implementation, Indonesia, through Bio Farma, has signed a cooperation agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate pandemic response on September 19, 2023. This collaboration is expected to increase more equitable access to vaccines needed for future pandemic countermeasures.
The Indonesian Minister of Health, Budi G. Sadikin, welcomed the achievements of CEPI and Bio Farma, especially to increase Indonesia's contribution to vaccine supply security and independence, especially in the ASEAN region and Bio Farma. global south.
"This collaboration can certainly encourage fast and efficient vaccine procurement for future pandemic countermeasures," said Minister of Health Budi.
Director General for Pharmaceutical and Medical Devices of the Indonesian Ministry of Health, L. Rizka Andalusia said, "Bio Farma has become one of the important players in the fight against infectious diseases by providing vaccine production for domestic and foreign needs. This collaboration is expected to be an opportunity for Bio Farma to strengthen its research and production capabilities in order to carry out its role as a supplier of vaccine products at the global level."
This collaboration will bring the latest vaccine production technologies, namely viral vector and mRNA to Indonesia and the ASEAN region and support product availability and increase vaccine production capacity.
In addition, Indonesia (Bio Farma) will also have a bioprocess laboratory facility that will be used for the development and testing of mRNA vaccine technology and the Bio Farma vaccine. viral vector. System of Good Manufacturing Practices (GMP will also be applied to facilities used for the production of vaccines to be used in Phase-2 and phase-3 Clinical trials and for limited commercial production purposes.
When the facility is fully operational, Indonesia will be able to supply mRNA vaccines and viral vector to cope with various types of extraordinary events within a relatively short time span, which is within 100 days of a new viral pathogen being identified.
Dr. Richard Hatchett, CEO of CEPI said "The world must be able to respond quickly and fairly if we are to reduce future outbreaks that have the potential to become pandemics. This collaboration with Indonesia through Bio Farma will make a new contribution to this goal by developing Bio Farma's world-class facilities with the latest production technology, namely, mRNA vaccines and viral vector. More importantly, the capabilities in producing mRNA vaccines implemented through this collaboration can provide accelerated and equitable access to vaccines for countries in the ASEAN region when facing the threat of an outbreak."
The same thing was conveyed by the President Director of Bio Farma, Shadiq Akasya "The collaboration between Bio Farma and CEPI will increase the capabilities of industries in developing countries to prepare themselves for the potential emergence of a pandemic. This collaboration is one of the achievements for Bio Farma in order to contribute to world health, and provide easy access to vaccine products in difficult times such as pandemics, especially in the ASEAN region."
The new production facility is part of CEPI's 100 Days Mission, supported by the G7 and G20 countries, which aims to reduce the time it takes to develop vaccines that are safe, effective in the event of an extraordinary event and accessible to many groups around the world.
This news was broadcasted by the Bureau of Communication and Public Services, Ministry of Health. For further information, please contact Halo Kemenkes through the number hotline 1500-567, SMS 081281562620, facsimile (021) 5223002, 52921669.
Head of Bureau of Communication and Public Service
dr. Siti Nadia Tarmizi, M.Epid
